NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Simcere Pharmaceutical Group »25/09/2009 [Company watch]
Simcere Teams Up with Cancer Centre to Develop Drugs

Simcere Pharmaceutical Group and Sun Yat-Sen University Cancer Center of Guangzhou have established a strategic relationship to develop cancer drugs.

 
by: ChinaBio Today:, Simcere Pharmaceutical Group and Sun Yat-Sen University Cancer Center of Guangzhou have established a strategic relationship to develop cancer drugs. In addition, the two companies will build a joint program to train personnel in advanced R&D. The company did not disclose any specifics about the nature of the cancer drug investigation, though the research at Sun Yat-Sen University Cancer Center focuses on innovative drugs. Three of Sun Yat-Sen University’s four campuses are in Guangzhou; the fourth is in Zhuhai. Founded in 1924 by Dr. Sun Yat-Sen, the MD who was also China s president, the university was originally known as National Kwangtung University, but it was renamed to honor Dr. Sun Yat-Sen following his death. Simcere develops and manufactures branded generic and innovative drugs. In the cancer sector, it produces Sinofuan, a 5-FU sustained release implant, and the anti-angiogenesis drug Endu, a recombinant human endostatin injection. Simcere currently produces and sells 45 products. It has SFDA approval to manufacture an additional 220 products, and it has 12 product candidates in development. In other news, Simcere said forty-two of its generic drugs have been included in China\'s Essential Drug List, though the company is currently producing only seven of these. Also, Simcere has filed a registration document that allows Jinsheng Ren, the company’s Chairman and CEO, to sell 17.9 million shares of the company (equivalent to 8.9 million of the listed ADSs), which represent 16% of the outstanding shares. The registration does not bind him to sell any or all of his holdings.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.